Boundless Bio, Inc. BOLD
Set alert
2.47 USD -0.01 -0.40%
At close · Oct 30
2.49 +0.02 +0.85%
After hours · Oct 30, 4:00 PM ET
2.43 Day range 2.59
1.05 52-week range 3.00
- YTD
- +105.83%
- 1 year
- +78.99%
- Open
- 2.53
- Prev close
- 2.48
- Mkt cap
- 57.08M
- Vol
- 47.01K
- Avg vol
- 179.01K
- EPS
- -2.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.43
- High
- 2.59
- Forward P/E
- -0.70
- Beta
- 0.00
- Short ratio
- 2.01
- Inst. own
- 75.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 6, 2025
- 50-d avg
- 2.91
- 200-d avg
- 5.46
- 1y target
- 14.50
2Y chart
Events in this range
- Nov 7, 2024Earnings: -0.74; estimate -0.76; surprise 2.63%
- Dec 13, 2024Downgrade: Guggenheim · Buy → Neutral
- Feb 6, 2025Earnings: —; estimate -0.74; surprise —%
Signals (82)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 26, 2026 | 5 days ago |
| RSI: Oversold | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 21, 2026 | 2 months ago |
| RSI: Overbought | Aug 18, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| RSI: Overbought | Aug 4, 2026 | 2 months ago |
| RSI: Overbought | Jul 24, 2026 | 3 months ago |
| RSI: Overbought | Jul 16, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 23, 2026 | 4 months ago |
| RSI: Overbought | Jun 23, 2026 | 4 months ago |
| SMA: Bearish | Jun 9, 2026 | 4 months ago |
| MACD: Sell Signal | Apr 28, 2026 | 6 months ago |
| RSI: Overbought | Apr 14, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Apr 6, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 6, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 26, 2026 | 7 months ago |
| SMA: Bearish | Mar 23, 2026 | 7 months ago |
| SMA: Bearish | Mar 23, 2026 | 7 months ago |
| SMA: Bullish | Mar 20, 2026 | 7 months ago |
| SMA: Bullish | Mar 20, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 17, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 13, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 9, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 6, 2026 | 7 months ago |
| MACD: Buy Signal | Feb 18, 2026 | 8 months ago |
| RSI: Oversold | Feb 4, 2026 | 8 months ago |
| SMA: Bearish | Jan 29, 2026 | 9 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 20, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| SMA: Bullish | Jan 6, 2026 | 9 months ago |
| SMA: Bearish | Dec 19, 2025 | 10 months ago |
| SMA: Bullish | Dec 17, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 5, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 30, 2025 | 1 year ago |
| SMA: Bullish | Oct 27, 2025 | 1 year ago |
| SMA: Bearish | Oct 23, 2025 | 1 year ago |
| RSI: Overbought | Oct 14, 2025 | 1 year ago |
| RSI: Overbought | Oct 8, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 29, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 19, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 5, 2025 | 1 year ago |
| SMA: Bearish | Sep 4, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 4, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 3, 2025 | 1 year ago |
| SMA: Bullish | Sep 2, 2025 | 1 year ago |
| SMA: Bullish | Aug 20, 2025 | 1 year ago |
| SMA: Bearish | Aug 19, 2025 | 1 year ago |
| SMA: Bullish | Aug 13, 2025 | 1 year ago |
| SMA: Bearish | Aug 8, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 5, 2025 | 1 year ago |
| SMA: Bullish | Jul 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 23, 2025 | 1 year ago |
| SMA: Bearish | May 27, 2025 | 1 year ago |
| MACD: Sell Signal | May 27, 2025 | 1 year ago |
| SMA: Bullish | May 15, 2025 | 1 year ago |
| MACD: Buy Signal | May 15, 2025 | 1 year ago |
| SMA: Bearish | May 14, 2025 | 1 year ago |
| MACD: Sell Signal | May 14, 2025 | 1 year ago |
| SMA: Bullish | May 13, 2025 | 1 year ago |
| SMA: Bearish | May 7, 2025 | 1 year ago |
| SMA: Bullish | Apr 29, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 15, 2025 | 1 year ago |
| RSI: Oversold | Apr 10, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 4, 2025 | 1 year ago |
| RSI: Oversold | Apr 4, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 14, 2025 | 1 year ago |
| RSI: Oversold | Mar 3, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 7, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 5, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 31, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 13, 2025 | 1 year ago |
Key statistics
- Market cap
- 57.53M
- Enterprise value
- -109.26M
- Trailing P/E
- 0.00
- Forward P/E
- -0.70
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.35
- EPS (TTM)
- -2.74
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -35.86M
- Total cash
- 167.14M
- Total debt
- 121.00K
- Return on equity
- -41.16%
- Shares outstanding
- 22.30M
- Short % of float
- 1.05%
- 50-day average
- 2.91
- 200-day average
- 5.46
Analyst view
Consensus: buy
Buy
Price target (mean) 14.50 +487.0% upside
Now 2.47
- Target (low)
- 14.00
- Target (mean)
- 14.50
- Target (high)
- 15.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 6, 2025
Expected Feb 6, 2025. Consensus EPS estimate -0.78333.
Financials — quick view
BOLD Revenue — quarterly 0
BOLD Net income — quarterly -23.69M
BOLD EPS — quarterly -1.06
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 6, 2025 | Dec 1, 2024 | -0.74 | — | — | — |
| Nov 7, 2024 | Sep 1, 2024 | -0.76 | -0.74 | +0.02 | +2.63% |
| Aug 12, 2024 | Jun 1, 2024 | -0.78 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | -0.78 | -0.77 | +0.01 | +1.28% |
| Feb 26, 2020 | Dec 1, 2019 | -1.02 | — | — | — |
| Nov 7, 2019 | Sep 1, 2019 | -1.07 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | Guggenheim | down | Buy | Neutral |
| Apr 22, 2024 | Leerink Partners | init | — | Outperform |
| Apr 22, 2024 | Guggenheim | init | — | Buy |
| Apr 22, 2024 | Piper Sandler | init | — | Overweight |
About Boundless Bio, Inc.
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- boundlessbio.com
News
- Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?
- Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?
- Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency
- Callio Therapeutics Appoints Zachary Hornby As CEO
- Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer
- Boundless Bio Q2 EPS $(1.06) Misses $(0.61) Estimate
- Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders
- Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)
Your note
Sign in to keep a note on BOLD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARCH VENTURE FUND IX, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 1, 2024 | 0 |
| BUROW KRISTINA M | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 1, 2024 | 0 |
| CRANDELL KEITH L. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 1, 2024 | 0 |
| LIM JONATHAN E | Director | Conversion of Exercise of derivative security | Apr 1, 2024 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 1, 2024 | 0 |
| WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN I L | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 1, 2024 | 556,233 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.97% | 3,338,084 | 8.61M | Sep 29, 2024 |
| RA Capital Management, L.P. | 9.78% | 2,180,631 | 5.63M | Sep 29, 2024 |
| Nextech Invest Ag | 5.51% | 1,228,069 | 3.17M | Sep 29, 2024 |
| Redmile Group, LLC | 4.59% | 1,023,548 | 2.64M | Sep 29, 2024 |
| Wellington Management Group, LLP | 4.25% | 947,612 | 2.44M | Sep 29, 2024 |
| Citadel Advisors Llc | 3.22% | 718,527 | 1.85M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 1.31% | 291,755 | 752.73K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 0.87% | 194,911 | 502.87K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.83% | 185,641 | 478.95K | Oct 30, 2024 |
| Fidelity Growth Company K6 Fund | 0.41% | 92,210 | 237.90K | Oct 30, 2024 |
| Fidelity Series Growth Company Fund | 0.35% | 78,900 | 203.56K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.29% | 65,223 | 168.28K | Aug 30, 2024 |